🔗 Share this article

While the US undertakes unprecedented revisions to its immunization recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots during the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief tenure at the FDA.

Planned Overhauls to Pediatric Vaccine Program

Health officials had intended to announce radical revisions to the pediatric immunization program in December, aligning the US with Denmark’s national calendar, sources say – a significant shift that would place the US out of alignment with much of the international standard with insufficient data for improved outcomes. This reveal has been pushed back until the coming year.

In place of the director of the vaccine center, Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to head the office this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for ending certain pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a population approximately the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – traditionally the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in drug development, regulation or leadership, which has been standard for former leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a sizeable institution. She is not an expert in industry regulation.”

Former heads of CBER would “grasp legal statutes and the underlying principles of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who led CBER have had.”

CDER has an immense workload at the agency, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic program authorizes a multitude of generic medications. There’s a biosimilars program, over-the-counter program and more, and every single one must be managed,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership element to the role, which supervises in excess of 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Initiatives

In response to questions about Høeg’s fitness for the role and whether this selection signifies more teamwork among FDA leaders on vaccines, a spokesperson said that the “questions are based on incorrect premises”.

“Her resume matches the duties of her position,” the representative stated, noting the period Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed rapid drug-approval program that allegedly troubled her preceding directors. “How are these drugs being chosen for this voucher program? Who makes the choices?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he said, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, except for shots.”

Established History on Vaccines

With immunizations, Høeg has a more established, if problematic, history, critics observe. She released a analysis using non-validated public submissions to assess the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming government encompassed revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she said after the election on a podcast. At the FDA, Høeg has allegedly floated the idea of excluding adolescent males from receiving Covid vaccines.

“She’s an all-around ideologue who starts off with her preconceived notions and works backwards to accommodate the evidence in a very disingenuous, fraudulent way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|